Key statistics dashboard for Arcellx, Inc. (ACLX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM).
Stock Data
| Price | $115.07 |
| Market Cap | $6.7B |
| Enterprise Value | $6.75B |
| Beta | 0.25 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -28.27 |
| Price / Book | 16.10 |
| P/S | 302.09 |
| EV/EBITDA | -34.09 |
| EV/Sales | 302.81 |
| EV/FCF | -31.74 |
| P/FCF | -31.67 |
| Earnings Yield | -3.53% |
| FCF Yield | -3.16% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -64.81% |
| EBIT Margin | -918.28% |
| EBITDA Margin | -888.31% |
| Operating Margin | -1135.61% |
| Net Margin | -1027.25% |
| Return on Equity | -55.42% |
| Return on Assets | -37.90% |
| Return on Invested Capital | -49.88% |
| Return on Capital Employed | -50.64% |
Financial Health
| Current Ratio | 4.44 |
| Quick Ratio | 4.44 |
| Cash Ratio | 0.77 |
| Debt / Equity | 0.24 |
| Debt / Assets | 15.94% |
| Net Debt / EBITDA | -0.08 |
| Interest Coverage | -10.45 |
Per-Share Data
| Revenue per share | 0.40 |
| Book Value per share | 7.15 |
| Cash per share | 8.00 |
| FCF per share | -3.78 |
| Tangible Book Value per share | 7.15 |
| Dividend per share | 0.00 |
Related companies: AKRO · ALKS · ARWR · CRSP · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of ACLX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks